937 related articles for article (PubMed ID: 28923369)
1. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
Daher A; de Groot J
Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
[TBL] [Abstract][Full Text] [Related]
2. Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells.
Grinshtein N; Rioseco CC; Marcellus R; Uehling D; Aman A; Lun X; Muto O; Podmore L; Lever J; Shen Y; Blough MD; Cairncross GJ; Robbins SM; Jones SJ; Marra MA; Al-Awar R; Senger DL; Kaplan DR
Oncotarget; 2016 Sep; 7(37):59360-59376. PubMed ID: 27449082
[TBL] [Abstract][Full Text] [Related]
3. Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma.
Skaga E; Kulesskiy E; Fayzullin A; Sandberg CJ; Potdar S; Kyttälä A; Langmoen IA; Laakso A; Gaál-Paavola E; Perola M; Wennerberg K; Vik-Mo EO
BMC Cancer; 2019 Jun; 19(1):628. PubMed ID: 31238897
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel small-molecule inhibitors of glioblastoma cell growth and invasion by high-throughput screening.
Wang L; Zhao H; Cui K; Yao L; Ren M; Hao A; Smollen P; Nie F; Jin G; Liu Q; Wong ST
Biosci Trends; 2012 Aug; 6(4):192-200. PubMed ID: 23006966
[TBL] [Abstract][Full Text] [Related]
5. A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells.
Visnyei K; Onodera H; Damoiseaux R; Saigusa K; Petrosyan S; De Vries D; Ferrari D; Saxe J; Panosyan EH; Masterman-Smith M; Mottahedeh J; Bradley KA; Huang J; Sabatti C; Nakano I; Kornblum HI
Mol Cancer Ther; 2011 Oct; 10(10):1818-28. PubMed ID: 21859839
[TBL] [Abstract][Full Text] [Related]
6. Biobanked Glioblastoma Patient-Derived Organoids as a Precision Medicine Model to Study Inhibition of Invasion.
Darrigues E; Zhao EH; De Loose A; Lee MP; Borrelli MJ; Eoff RL; Galileo DS; Penthala NR; Crooks PA; Rodriguez A
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639060
[TBL] [Abstract][Full Text] [Related]
7. Tapered microtract array platform for antimigratory drug screening of human glioblastoma multiforme.
Cha J; Koh I; Choi Y; Lee J; Choi C; Kim P
Adv Healthc Mater; 2015 Feb; 4(3):405-11. PubMed ID: 25230171
[TBL] [Abstract][Full Text] [Related]
8. Glioblastoma targeted therapy: updated approaches from recent biological insights.
Touat M; Idbaih A; Sanson M; Ligon KL
Ann Oncol; 2017 Jul; 28(7):1457-1472. PubMed ID: 28863449
[TBL] [Abstract][Full Text] [Related]
9. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
10. Proscillaridin A is cytotoxic for glioblastoma cell lines and controls tumor xenograft growth in vivo.
Denicolaï E; Baeza-Kallee N; Tchoghandjian A; Carré M; Colin C; Jiglaire CJ; Mercurio S; Beclin C; Figarella-Branger D
Oncotarget; 2014 Nov; 5(21):10934-48. PubMed ID: 25400117
[TBL] [Abstract][Full Text] [Related]
11. Toward precision medicine in glioblastoma: the promise and the challenges.
Prados MD; Byron SA; Tran NL; Phillips JJ; Molinaro AM; Ligon KL; Wen PY; Kuhn JG; Mellinghoff IK; de Groot JF; Colman H; Cloughesy TF; Chang SM; Ryken TC; Tembe WD; Kiefer JA; Berens ME; Craig DW; Carpten JD; Trent JM
Neuro Oncol; 2015 Aug; 17(8):1051-63. PubMed ID: 25934816
[TBL] [Abstract][Full Text] [Related]
12. Using genomics to guide treatment for glioblastoma.
Young JS; Prados MD; Butowski N
Pharmacogenomics; 2018 Oct; 19(15):1217-1229. PubMed ID: 30203716
[TBL] [Abstract][Full Text] [Related]
13. An in silico screen links gene expression signatures to drug response in glioblastoma stem cells.
Riddick G; Song H; Holbeck SL; Kopp W; Walling J; Ahn S; Zhang W; Fine HA
Pharmacogenomics J; 2015 Aug; 15(4):347-53. PubMed ID: 25446780
[TBL] [Abstract][Full Text] [Related]
14. A gentle introduction to understanding preclinical data for cancer pharmaco-omic modeling.
Piyawajanusorn C; Nguyen LC; Ghislat G; Ballester PJ
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34368843
[TBL] [Abstract][Full Text] [Related]
15. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.
Lee HW; Lee JI; Lee SJ; Cho HJ; Song HJ; Jeong DE; Seo YJ; Shin S; Joung JG; Kwon YJ; Choi YL; Park WY; Lee HM; Seol HJ; Shim YM; Joo KM; Nam DH
Clin Cancer Res; 2015 Mar; 21(5):1172-82. PubMed ID: 25549722
[TBL] [Abstract][Full Text] [Related]
16. Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer.
Tsoli M; Wadham C; Pinese M; Failes T; Joshi S; Mould E; Yin JX; Gayevskiy V; Kumar A; Kaplan W; Ekert PG; Saletta F; Franshaw L; Liu J; Gifford A; Weber MA; Rodriguez M; Cohn RJ; Arndt G; Tyrrell V; Haber M; Trahair T; Marshall GM; McDonald K; Cowley MJ; Ziegler DS
Cancer Biol Ther; 2018; 19(12):1078-1087. PubMed ID: 30299205
[TBL] [Abstract][Full Text] [Related]
17. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
Albin N; Mc Leer A; Sakhri L
Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
[TBL] [Abstract][Full Text] [Related]
18. An orthotopic glioblastoma animal model suitable for high-throughput screenings.
Pudelko L; Edwards S; Balan M; Nyqvist D; Al-Saadi J; Dittmer J; Almlöf I; Helleday T; Bräutigam L
Neuro Oncol; 2018 Oct; 20(11):1475-1484. PubMed ID: 29750281
[TBL] [Abstract][Full Text] [Related]
19. Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression data.
Cheng HW; Liang YH; Kuo YL; Chuu CP; Lin CY; Lee MH; Wu AT; Yeh CT; Chen EI; Whang-Peng J; Su CL; Huang CY
Cell Death Dis; 2015 May; 6(5):e1753. PubMed ID: 25950483
[TBL] [Abstract][Full Text] [Related]
20. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]